Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Titan Pharmaceuticals (AMEX:TTP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 31Price hit new 52-week low ($9.61)
Aug 15Earnings Announcement
Location
400 Oyster Point Blvd., Suite 505
South San Francisco, CA 94080
Phone: (650) 244-4990
Fax: (650) 244-4956
Email: info@titanpharm.com
Employees (last reported count): 46
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Related Links
 ·Search Yahoo! for related links...
Ownership
·Insider and 5%+ Owners: 21%
·Over the last 6 months:
 · one insider buy; 3,000  shares
 · 3 insider sells; 207.0K shares
  (3.4% of insider shares)
·Institutional: 75% (95% of float)
(224 institutions)
·Net Inst. Selling: 324.0K shares (+1.60%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases. The Company's product development programs focus on large pharmaceutical markets with significant unmet medical needs and commercial potential. The Company has nine products in development, seven of which are in clinical development, with two products in expanded human trials for safety and efficacy, known as Phase III clinical trials. The Company has five products in trials for preliminary efficacy and dosing, and in trials for initial human safety and evidence of efficacy, known as Phase II and Phase I/II clinical trials, respectively. In addition to these programs, the Company has two products in preclinical development. Some of the Company's preclinical product development is conducted through its two consolidated subsidiaries, Ingenex, Inc. and ProNeura, Inc.
More from Market Guide: Expanded Business Description

Financial Summary
Titan Pharmaceuticals develops proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases. For the six months ended 6/30/01, revenues totalled $3.5 million, up from $616 thousand. Net loss rose 5% to $6.4 million. Revenues reflect the license fee payment from Novartis Pharma AG for the development of iloperidone in Japan. Higher loss reflects increased research and development expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Louis Bucalo, M.D., 42
Chairman, Pres, CEO
$262K
Robert Farrell, 51
CFO, Exec. VP
195K
Sunil Bhonsle, 51
COO, Exec. VP
203K
Victor Bauer, Ph.D., 65
Exec. Director of Corp. Devel., Director
--  
Richard Allen, Ph.D., 58
Exec. VP, Cell Therapy
203K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:TTPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 31-Aug-2001
$9.61 
Recent Price$9.75 
52-Week High
on 29-Sep-2000
$65.30 
Beta0.99 
Daily Volume (3-month avg)306.6K
Daily Volume (10-day avg)164.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-79.4%
52-Week Change
relative to S&P500
-72.4%
Share-Related Items
Market Capitalization$269.5M
Shares Outstanding27.6M
Float21.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.99 
Earnings (ttm)-$0.72 
Earnings (mrq)-$0.07 
Sales (ttm)$0.17 
Cash (mrq)$4.09 
Valuation Ratios
Price/Book (mrq)2.44 
Price/EarningsN/A 
Price/Sales (ttm)55.71 
Income Statements
Sales (ttm)$4.72M
EBITDA (ttm)-$25.0M
Income available to common (ttm)-$19.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-18.59%
Return on Equity (ttm)-19.30%
Financial Strength
Current Ratio (mrq)39.08 
Debt/Equity (mrq)0 
Total Cash (mrq)$113.1M
Short Interest
As of 8-Aug-2001
Shares Short706.0K
Percent of Float3.2%
Shares Short
(Prior Month)
0 
Short Ratio1.36 
Daily Volume519.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.